Specific lymphocyte subsets predict response to adoptive cell therapy using with a more differentiated effector phenotype seemed to be the most highly active component. 7
In addition, for the first time we screened for the expression of negative T-cell costimulatory 8 molecules (PD-1, BTLA, and TIM-3) in TIL and how these are associated with clinical response. 9
Unexpectedly, we found that CD8 + T cells expressing BTLA (B-and T-lymphocyte attenuator) 10 were highly associated with clinical response. This cell subset may be a potentially powerful 11 new biomarker in TIL therapy. 12 13   14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30 Introduction   1  2 Metastatic melanoma is an aggressive form of cancer highly resistant to traditional forms of 3 therapy, such as chemotherapy and radiation therapy (1) . Response rates and survival for 4 patients with advanced stages (IIIc and IV) in response to chemotherapy, such as dacarbazine 5 and temozolomide, have been relatively poor (2). Drugs targeting activated oncogenes of the 6 mitogen-activated protein kinase (MAPK) pathway (3), such as B-RAF V600E has also been 7 actively pursued (4). Recently, a B-RAF V600E inhibitor has been approved by the FDA recently 8 (5). However, although this drug was shown to induce objective tumor regression in a high 9
percentage of patients, these responses are turning out to be of limited duration (6) . Originally, 10 due to its relative refractoriness to chemotherapy and radiation therapy, melanoma has been 11 studied as a target for immunotherapy more than many other forms of cancer (7). Most 12 melanoma metastases contain lymphocytic infiltrates, including T cells that recognize melanoma Another promising form of immunotherapy for metastatic melanoma is adoptive cell 19 therapy (ACT) using the infusion of autologous tumor-infiltrating lymphocytes (TIL) expanded 20 ex vivo combined with HD IL-2 therapy (10, 11) . ACT involves the isolation of viable tumor 21 tissue and the expansion of TIL with IL-2 over 4-5 weeks from tumor fragments placed in 22 culture (12). The TIL are then further expanded in larger-scale using anti-CD3 activation and 23 exogenous IL-2 in the presence of autologous or allogeneic irradiated feeder cells (12). This 24 100-150 billion cells for infusion (8, 12) . Durable responses to TIL therapy have been improved 1 by the addition of a preparative lymphodepleting regimen using a combination of 2 cyclophosphamide and fludarabine (10, 13) which leads to an increase in persistence of the 3 transferred cells (13) . Further improvements for this approach will be dependent on an increased 4 understanding of the mechanism of TIL antitumor activity, such as determining which 5 lymphocyte subtypes within the heterogeneous bulk population of cells are responsible for tumor 6 regression. Overall, a better understanding of the nature of the T cells mediating objective anti-7 tumor responses during ACT will allow us to select the most active cell subsets to transfer into 8 patients, or tailor TIL expansion procedures to preferentially expand these active T-cell 9 populations for therapy to improve clinical response rates. 10 We have undertaken a Phase II ACT clinical trial for metastatic melanoma using expanded 11 TIL followed by HD IL-2 in patients pre-treated with a cyclophosphamide and fludarabine 12 lymphodepleting regimen (10, 13) . In this paper, we report results on the clinical response rates 13 of first 31 TIL-treated patients and an analysis of possible predictive biomarkers of therapeutic 14 effectiveness, including phenotypic markers and telomere length in the infused T-cells. 15
16

Materials and Methods
17
Patient population, overall TIL expansion process, and therapy 18 this paper is on the first 31 treated patients. Both male and female patients with stage IV 1 melanoma, Stage III in-transit disease, or recurrent regional nodal disease over the age of 18 2 were enrolled following informed consent. One patient under the age of 18 (a 15-year old 3 female; Patient #2247) was enrolled after a compassionate exemption was approved by the FDA. 4
All types of prior therapy were allowed, including chemotherapy, biochemotherapy, targeted 5 therapy with tyrosine kinase inhibitors and anti-angiogenic agents, and immunotherapy. 6
Patients with brain metastases ≤1 cm were eligible. Please refer to clinical trial NCT00338377 7 in the NCI website (http://www.cancer.gov/clinicaltrials) for further details on patient inclusion 8 and exclusion criteria. Table S1 (Supplementary Data on-line) and Table 1 also provide further  9 information on the accrued patient clinical and demographic characteristics for this study. All 10 patients were HLA typed at the HLA-A locus in the MD Anderson HLA Typing Laboratory. expansion, while in some cases two to three smaller nodules were used. In previous studies we 21 and others have found no association between the success of TIL expansion and the site of tumor 22 resection (14) . TIL were expanded from 3-5 mm 3 cut tumor fragments according to previously 23 using manual dissection. The TIL expanded from the tumor fragments (pre-REP TIL) to 1 minimum of a total of 48 x 10 6 cells were cryopreserved and kept for further expansion (Fig.  2 S1A) for therapy according to the criteria in the clinical protocol. TIL that did not expand to 3 these minimal numbers were not further expanded and these patients did not go on to receive 4 treatment. Cryopreserved pre-REP TIL from patients to be treated were thawed and further 5 expanded using the rapid expansion protocol (REP) to generate the final TIL infusion product 6 (post-REP TIL) (12). A small sample of the pre-REP TIL before cryopreservation was analyzed 7
for anti-tumor reactivity as a possible predictive biomarker using an autologous melanoma cell 8 line generated from the patient (when possible), or a semi-allogeneic melanoma cell line that had 9 at least one matched HLA-A allele, as targets. Details on the methodology used to expand TIL 10 for therapy and the determination of pre-REP TIL anti-tumor reactivity can be found in 11
Supplementary Methods on-line. given approximately 21 days after TIL infusion in a similar manner (Fig. S1B on-line) . 22
Hematologic and biochemical parameters were monitored daily during IL-2 administration. 23
Intravenous blood samples (10 ml) were collected from patients before and after 24
Research. 
Measurement of clinical responses by irRC and RECIST 7
Tumor response to therapy was done using the immune-related response criteria (irRC), a 8 modified version of the WHO criteria (16) . Response evaluation criteria in solid tumors 9 (RECIST 1.1) was also used to assess clinical response (17) to compare to the irRC response 10 rates found. Throughout the study, irRC was used to determine official response rates and 11 progression-free survival times. For the purposes of this paper, we define responders as complete 12 and partial responders and non-responders as patients with progressive or stable disease by 13 determining the the best overall response (BOR) using irRC (irBOR). Details how and when 14 tumor burden measurements were taken and irRC applied to determining the type of clinical 15 response and whether any progression had occurred can be found in Supplementary Methods and 16 
Tracking of TCR Vβ clonotypes post-infusion by gene cloning and sequencing 16
Total RNA was isolated from TIL or patients' PBMC after adoptive transfer using Qiagen 17
RNeasy Kit (74104). RNA quality was monitored by agarose gel electrophoresis to assess RNA 18 degradation. TCR Vβ specific cDNA was synthesized using Clonetech 5' RACE Smarter kit. 19
The primer in cDNA synthesis specifically binds to the Vβ constant region and can recognize 20 both C1 and C2 (21) . During cDNA synthesis, a 5' end adapter was added to each cDNA. 21
Nested primers for adapter and Vβ constant regions were used for PCR amplification. ) were removed. Previous data from our group has found that the 13 success rate in meeting this threshold for pre-REP TIL expansion is about 62% regardless of the 14 type of prior therapy before the tumor harvest (14) . Patients with cryopreserved pre-REP TIL 15 having progressive disease and who met eligibility criteria were treated after further expansion of 16 their thawed TIL using the REP. Only patients treated with their final post-REP TIL product 17 were included in this study. Table S1 (Table 1) . 3 4 Treatment-related toxicity and measurement of hematopoietic parameters 5
Patients experienced only transient, reversible adverse reactions (e.g., fever, chills, shortness of 6 breath, increased heart rate) in the few hours following TIL transfer. No Grade 3 or 4 toxicities 7 according to the National Cancer Institute Common Toxicity Criteria (NCICTC) were noted after 8 TIL infusion before HD IL-2 therapy (27). Hematologic toxicities due to the preparative 9 chemotherapy were anticipated and transient. Neutropenia and lymphopenia were observed in 10 all patients as expected. All patients were also treated with platelet transfusions and red blood 11 cell transfusion as needed and their counts eventually increased back to normal levels. 12 immunotherapies as opposed to chemotherapies. We noted objective tumor regression of tumors 5 in multiple sites in responding patients, including sub-cutaneous, lung, liver, lymph node, and of 6 tumors growing attached to major organs such as the spleen and heart. Fig. 1 shows examples of 7 objective tumor regressions at visceral and non-visceral sites following TIL infusion in two 8 representative patients by CT scans and photographs. We also noted in some cases that a mass 9 underwent a durable partial regression by CT, and the remnant lesion was no longer 2- burden, as shown in a waterfall plot analysis (Fig. 2) . 23
Research. We also measured responses using RECIST 1.1 (17) and found that the BOR was 41.9% 1 (13/31). Overall, two patients scored as responders with irRC (16), but were non-responders 2 (PD) using RECIST due to the development of new lesions detected after TIL infusion. One of 3 these patients (#2262) developed a small brain lesion 2 months after TIL ACT that was 4 surgically resected, but was still considered as progression-free according to irRC. At follow-up, 5 this patient was progression-free by irRC after surgery for >22 months and the initial sites of 6 disease continue to respond. The other patient (#2267) had a PR by irRC but had a developing 7 new small brain lesion by 2 months after TIL treatment. This patient was treated by whole brain 8 radiation and was alive >22 months after TIL therapy. 9
Overall survival (OS) and progression-free survival (PFS) were estimated from the 10 treatment start date for all 31 patients (Fig. S4 on-line) . The median OS time was not reached by 11 the end study; the median PFS time was 7.6 months (95% CI: 4.1-22.2 months). The 6-month 12 OS and PFS rates were 81% (95% CI: 62-91%) and 57% (95% CI: 38-73%), respectively. In 13 order to compare unbiased differences in OS and PFS between responders and non-responders, 14 we performed a landmark survival analysis (28) starting at the 3-month time point after TIL 15 infusion (Fig. S5 on-line) . The landmark 6-month PFS rates for irRC responders and non-16 responders were 88% (95% CI: 39-98%) and 47% (95% CI: 21-69%), respectively. The 17 landmark 18-month OS rates for responders and non-responders at the landmark were 87% (95% 18 CI: 36-98%) and 48% (95% CI: 26-67%), respectively. The landmark median OS time for non-19 responders was 463 days (95% CI: 76 -. days) but could not be estimated for responders. The 20 landmark median PFS times for non-responders and responders were 105 days (95% CI 33-. 21 days) and 577 days (95% CI 138-. days). Change in tumor burden over time in all treated 22 patients over the first 20-22 months after TIL infusion can be found in Fig. S6 on- 
showed a more protracted decrease in tumor burden. Interestingly, Patient #2175 (non-1 responder) exhibited a prolonged SD with >29 months PFS by irRC (Fig. S6) . Five responding 2 patients, although achieving a response by irRC, were treated with additional therapies for 3 renewed progression within the study period; these patients are listed in Fig. S6 (panel C)  4 together with the time point and type of therapy they received after TIL. 5 6 Pre-REP anti-tumor reactivity and clinical response 7
We determined the anti-tumor reactivity of the pre-REP TIL as a possible predictive biomarker 8 for irRC clinical response. Pre-REP TIL were cultured in IL-2 from tumor fragments for 5 9 weeks and tested with either autologous melanoma tumor cell lines (if available) or semi-10 allogeneic cell lines matched minimally at one HLA-A allele. We have found that IL-2-11 expanded TIL were functional and responded to polyclonal TCR using anti-CD3 stimulation in 12 both IFN-γ and CTL assays (data not shown). The percentage of treated patients having TIL 13 exhibiting significant anti-tumor-specific IFN-γ responses (≥100 pg/ml IFN-γ after subtraction of 14 controls) either against an autologous or at least one allogeneic matched melanoma cell line was 15 71% (22/31). We were able to generate an autologous melanoma cell line for testing the pre-16 REP TIL for 17/31 (55%) of the patients and among these all but two TIL had specific anti-17 tumor IFN-γ responses. No significant association was found between positive anti-tumor 18 reactivity and clinical response (p= 0.46; Table S3 ). 19
20
Immunophenotyping of infused TIL using flow cytometry 21
As shown in Table 1 , the total amount of infused TIL varied across the patient population. 22
Responding patients were infused with significantly more TIL (median 99 x 10 9 cells) than non-23 responders (median 55 x 10 9 ) (p= 0.0003; Table S4 , Fig 3A) . We further analyzed the different 24 clinical response, while those lacking BTLA co-expression were not (Fig. 5D) . 2 3
Analysis of TIL Vβ clonotype persistence in vivo 4
Persistence of infused TIL for at least 1 month following adoptive transfer into lymphoablated 5 melanoma patients has been previously found to be associated with objective clinical response to 6 therapy (21). We used a TCR Vβ cloning and CDR3 sequencing approach used previously to 7 track the changes in dominant TCR Vβ clonotypes in PBMC in five responding patients up to 22 8 months post TIL infusion (patients #2131, #2150/2153, #2258, #2124, and #2180). As shown in 9 Table S5 (on-line), some dominant Vβ clonotypes in the original TIL persisted long-term over 10 the entire 22-month period (e.g., Vβ24-1 and Vβ12-3 in Patient #2150/2153, and Vβ4-1 and 11 Vβ29 in Patient# 2131). However, a significant number of dominant TIL Vβ clonotypes also 12 became undetectable after 1 month, while other previously undetectable Vβ clonotypes emerged 13 and expanded over the following months (Table S5) . Similar results were found in other 14 responding patients. 15
16
TIL from responders and non-responders did not significantly differ in telomere length 17
The telomere length of infused TIL products was retrospectively evaluated from cryopreserved 18 samples. A Southern blot method using complementary telomere repeat probes on restriction 19 enzyme-digested genomic DNA was performed to determine not only the average telomere 20 length found in each TIL sample, but also range of telomere lengths that occur (23, 33). 21 Southern blotting has been the most used approach to determine both of these parameters (22, 22 23). This analysis revealed that each TIL sample did not have a single fixed telomere length for 23
Research. In this study, we demonstrate that adoptive transfer of highly expanded melanoma TIL into 10 patients with metastatic melanoma who had prior lymphoablation can mediate partial and even 11 complete regression of disease at multiple organ sites. Our reported clinical response rates using 12 irRC were 48.4% (15/31 responders) and are comparable to previously reported TIL therapy 13 trials using RECIST (10, 11) . A large proportion of our responders (12/15) had >70% tumor 14 regression with four responders achieving a complete reduction in their measureable tumor 15 burden. Only two of these patients were scored as CR since they continued to have non -16 measureable, yet stable, lesions in the bone. Our landmark analysis revealed a significant 17 increase in OS of TIL responders over non-responders (p=0.033). These results suggest that an 18 initial response to TIL therapy is of significant clinical benefit in these patients. 19
The total number of infused TIL was a critical parameter associated with clinical response, 20 with responders being infused on average with almost twice the number of TIL as non-21 responders. These results suggest that ACT using TIL should aim to infuse as many T cells as 22 possible to ensure more consistent clinical benefit. We also tested whether analysis of TIL anti-23 tumor reactivity at the pre-REP stage can be a predictive biomarker of clinical response. This 1 would be beneficial in selecting which TIL to further expand in large-scale for therapy. 2 However, our data was inconclusive and suggests that positive IFN-γ secretion against melanoma 3 cells at this pre-REP stage may not be predictive and that other biomarkers in the TIL, tumor 4 microenvironment, or differences in systemic factors may ultimately play a defining role. 5
However, measurement of anti-tumor reactivity of TIL in the actual infusion products (pos-REP) 6 will be needed to make a more definitive conclusion regarding this issue. Another correlative parameter studied in T-cell therapy is the telomere repeat lengths of 17 infused TIL. Telomere length has been linked to shorter persistence of transferred TIL in vivo 18 (47). Using the Southern blotting approach, we found no significant difference between the 19 mean telomere length in TIL between responders and non-responders. Responders had a 20 tendency to have slightly longer telomere lengths, but this was found not to be significant. It is 21 also important to point out that the median telomere lengths found in our study for both 22 responders and non-responders here (median of 5.9 Kb and 5.4, respectively), as well as in 23 previous TIL therapy studies (36) , are in fact within the same range as those found in original 24 studies on human lymphocyte senescence showing telomeric repeat lengths in the range of 4.7-1 6.3 Kb in senescing T cells by Southern blotting (23). However, our Southern blotting analysis 2 also revealed that a considerable heterogeneity existed in the telomere lengths of infused TIL, 3 with a range of 3 and 11 Kb found in the blots of both responders and non-responders. Thus, it is 4 possible that smaller sub-populations of TIL still retain relatively long telomeres above this 5 senescent range (>6.3 Kb) with a higher capacity to persist and expand in vivo, while other TIL 6 populations with shorter telomere lengths have a reduced cell division potential and lifespan. 7
Overall, our data underscores the difficulty in interpreting the impact of telomere length as a 8 biomarker because there is not one single telomere length that can be assigned to the entire TIL 9 population and considerable heterogeneity exists. 10
In summary, we have found that adoptive transfer of TIL expanded ex vivo can induce a 11 high rate of objective tumor regression in unresectable metastatic melanoma patients and that 12 these responses can be long-lasting in a significant fraction of treated patients. Moreover, our 
